This is a narrative update with no hard catalysts — monitor for actual clinical trial enrollment updates or regulatory interactions for stenoparib. The CLIA certification and patent awards are incremental positives but do not change the company's near-term cash runway or approval timeline.
Price Chart
Executive Summary
Allarity Therapeutics issued a press release highlighting recent advances in its Drug Response Predictor (DRP) technology, including newly awarded patents and CLIA lab certification, intended to support the clinical development of stenoparib and expand external partnership opportunities. The filing contains no financial data, no clinical data updates, and no regulatory milestones — it is a routine operational update with forward-looking statements only.
Key Facts
- Allarity announced recently awarded patents for its DRP technology and CLIA certification of its in-house lab.
- The press release reiterates plans to use DRP to inform patient selection for a potential pivotal trial of stenoparib.
- No financial figures, clinical results, or regulatory milestones were reported in this filing.
- The company remains a Phase 2 clinical-stage company with no approved products or disclosed revenue.
Financial Impact
No financial impact disclosed; the filing contains no revenue, earnings, cash flow, or deal value figures.
Risk Factors
- Allarity has no approved products and requires additional financing to advance stenoparib through clinical trials.
- Forward-looking statements about DRP-guided pivotal trials and FDA approval are aspirational and subject to significant regulatory and clinical risk.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-105457 |
| Document: ea030729801ex99-1.htm | 0001213900-26-105457 |
| Document: 0001213900-26-105457-index-headers.html | 0001213900-26-105457 |
| Document: 0001213900-26-105457-index.html | 0001213900-26-105457 |
| Document: 0001213900-26-105457.txt | 0001213900-26-105457 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9296 (−10.62%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 | awaiting T+20 | — | $0.9296 (−3.68%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9296 (−4.01%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9296 (−19.52%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9296 (−20.55%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9296 (−23.80%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9296 (−32.15%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9296 (−30.11%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9296 (−31.65%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9296 (−34.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers